Salvage chemotherapy regimens in relapsed or refractory Hodgkin lymphoma
| Chemotherapy regimen . | No. of patients . | CR (%), 95% CI . | PR (%), 95% CI . | ORR (%), 95% CI% . | Grade 3/4, NEUT (%) . | Grade 3/4, TCP (%) . | Grade 3/4, VOM (%) . | Toxic deaths (%), 95% CI . |
|---|---|---|---|---|---|---|---|---|
| Dexa-BEAM6 | 144 | 27, 20-34 | 54, 46-62 | 81, 75-87 | NS | NS | NS | 5, 1-9 |
| Mini-BEAM19 | 55 | 49, 35-63 | 33, 21-47 | 82, 69-91 | 86 | 60 | NS | 2, 0.1-10 |
| ICE21 | 65 | 26, 16-39 | 59, 46-71 | 85, 74-92 | NS | NS | NS | 0, 0-5 |
| DHAP q2wk30 | 102 | 21, 13-29 | 68, 59-77 | 89, 83-95 | 88 | 69 | 26 | 0, 0-4 |
| GDP32 | 23 | 17, 5-39 | 52, 31-73 | 69, 47-87 | 9 | 13 | 13 | 0, 0-15 |
| GVD38 * | 91 | 19 | 51 | 70 | 63 | 14 | 0 | 0 |
| IEV35 | 51 | 76, 60-88 | 84, 71-93 | 100† | NS | NS | 0 | |
| MINE34 | 157 | NS | NS | 75, 64-84 | NS | NS | NS | 5‡ |
| IV36,39 | 47 | 45, 30-60 | 38, 25-54 | 83, 69-92 | 65 | 0 | 2 | NS |
| Chemotherapy regimen . | No. of patients . | CR (%), 95% CI . | PR (%), 95% CI . | ORR (%), 95% CI% . | Grade 3/4, NEUT (%) . | Grade 3/4, TCP (%) . | Grade 3/4, VOM (%) . | Toxic deaths (%), 95% CI . |
|---|---|---|---|---|---|---|---|---|
| Dexa-BEAM6 | 144 | 27, 20-34 | 54, 46-62 | 81, 75-87 | NS | NS | NS | 5, 1-9 |
| Mini-BEAM19 | 55 | 49, 35-63 | 33, 21-47 | 82, 69-91 | 86 | 60 | NS | 2, 0.1-10 |
| ICE21 | 65 | 26, 16-39 | 59, 46-71 | 85, 74-92 | NS | NS | NS | 0, 0-5 |
| DHAP q2wk30 | 102 | 21, 13-29 | 68, 59-77 | 89, 83-95 | 88 | 69 | 26 | 0, 0-4 |
| GDP32 | 23 | 17, 5-39 | 52, 31-73 | 69, 47-87 | 9 | 13 | 13 | 0, 0-15 |
| GVD38 * | 91 | 19 | 51 | 70 | 63 | 14 | 0 | 0 |
| IEV35 | 51 | 76, 60-88 | 84, 71-93 | 100† | NS | NS | 0 | |
| MINE34 | 157 | NS | NS | 75, 64-84 | NS | NS | NS | 5‡ |
| IV36,39 | 47 | 45, 30-60 | 38, 25-54 | 83, 69-92 | 65 | 0 | 2 | NS |
ASCT indicates autologous stem cell transplant; BEAM, BCNU, etoposide, ara-C, melphalan; CI, confidence interval; CR, complete response; DHAP, dexamethasone, ara-C, cisplatin; GDP, gemcitabine, dexamethasone, cisplatin; GVD, gemcitabine, vinorelbine, doxil (liposomal doxorubicin); ICE, ifosfamide, carboplatin, etoposide; IEV, ifosfamide, etoposide, vinorelbine; IV, ifosfamide; vinorelbine; MINE, mitoguazone, ifosfamide, vinorelbine; etoposide; NEUT, neutropenia; NS, not stated; ORR, overall response rate; PR, partial response; q2wk, every 2 weeks; TCP, thrombocytopenia; and VOM, vomiting.
Mucositis reported in 9%.
All patients experienced grade IV neutropenia.
The 5% toxic death rate included patients undergoing ASCT.